---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026107"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:04:56.225148+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma receives Nasdaq MVLS deficiency notice; must regain compliance by Feb 3, 2025

## Summary
- Nasdaq notified NRx on Aug 6 that MVLS was below $35M minimum from June 14 to Aug 5, 2024.
- Company has 180 days (until Feb 3, 2025) to achieve MVLS >= $35M for 10 consecutive days.
- Failure to regain compliance may result in delisting; Company can appeal but no assurance of success.

## SEC filing metadata
- accession: 0001437749-24-026107
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774924026107/0001437749-24-026107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774924026107/nrxp20240812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026107
- JSON: https://secwatch.observer/filing/0001437749-24-026107.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.